2. Search Result
Search Result
Results for "

dual MNK/p70S6K inhibitors

" in MedChemExpress (MCE) Product Catalog:

2066

Inhibitors & Agonists

3

Screening Libraries

27

Fluorescent Dyes

18

Biochemical Assay Reagents

81

Peptides

6

MCE Kits

22

Inhibitory Antibodies

82

Natural
Products

36

Recombinant Proteins

49

Isotope-Labeled Compounds

50

Antibodies

16

Click Chemistry

11

Oligonucleotides

6

GMP Molecules

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-13595
    Chrysophanol
    5+ Cited Publications

    Chrysophanic acid

    		 EGFR Cancer
    Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.
    Chrysophanol
  • HY-158426
    2-APQC
    1 Publications Verification

    		 Sirtuin Cardiovascular Disease
    2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (Kd=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .
    2-APQC
  • HY-12299
    WH-4-023
    5 Publications Verification

    dual LCK/SRC inhibitor

    		 Src Cancer
    WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.
    WH-4-023
  • HY-12493A
    LY-2584702 tosylate salt
    5 Publications Verification

    		 Ribosomal S6 Kinase (RSK) Cancer
    LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
    LY-2584702 tosylate salt
  • HY-16071
    AT13148
    2 Publications Verification

    		 Akt PKA ROCK Ribosomal S6 Kinase (RSK) Cancer
    AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.
    AT13148
  • HY-N0847
    Micheliolide
    5+ Cited Publications

    		 NF-κB PI3K Akt TGF-beta/Smad Inflammation/Immunology Cancer
    Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .
    Micheliolide
  • HY-14774
    Monepantel
    1 Publications Verification

    AAD1566; NUZ-001

    		 mTOR Parasite nAChR Autophagy Infection Neurological Disease Cancer
    Monepantel (AAD1566, NUZ-001), an antiparasitic agent, is an orally active mTOR inhibitor. Monepantel triggers autophagy through the deactivation of mTOR/p70S6K signalling pathway. Monepantel is a positive allosteric modulator of a nematode-specific clade of nAChR subunits. Monepantel can be used for the study of amyotrophic lateral sclerosis (ALS) and ovarian cancer .
    Monepantel
  • HY-135140
    Methyltetrazine-amine

    		Biochemical Assay Reagents Others
    Methyltetrazine-amine, a tetrazine compound, is used for the site-specific dual functionalization of the resulting bioconjugates .
    Methyltetrazine-amine
  • HY-13260
    CCT128930
    5+ Cited Publications

    		 Akt Autophagy Apoptosis Cancer
    CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC50=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). Antitumor activity.
    CCT128930
  • HY-109108A
    Valemetostat tosylate
    5 Publications Verification

    DS-3201 tosylate

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
    Valemetostat tosylate
  • HY-100501
    M2698
    1 Publications Verification

    MSC2363318A

    		 Ribosomal S6 Kinase (RSK) Akt Cancer
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .
    M2698
  • HY-110313
    SB-747651A dihydrochloride
    1 Publications Verification

    		 p38 MAPK Inflammation/Immunology
    SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research .
    SB-747651A dihydrochloride
  • HY-N10303
    Withangulatin A
    1 Publications Verification

    		 COX Parasite Reactive Oxygen Species (ROS) Apoptosis p38 MAPK NF-κB Akt mTOR TGF-beta/Smad Inflammation/Immunology Cancer
    Withangulatin A is the inhibitor for COX-2. Withangulatin A inhibits MAPK, NF-κB, Akt/mTOR/p70S6K pathway, exhibits antitumor, anti-inflammatory and trypanocidal activities .
    Withangulatin A
  • HY-12059
    AT7867
    5 Publications Verification

    		 Akt PKA Ribosomal S6 Kinase (RSK) Cancer
    AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
    AT7867
  • HY-112424
    Tinodasertib
    1 Publications Verification

    ETC-206

    		 MNK Cancer
    Tinodasertib (ETC-206) is a selective MNK1 and MNK2 inhibitor with IC50s of 64 nM and 86 nM, respectively.
    Tinodasertib
  • HY-N0008
    Orcinol glucoside

    		Wnt p38 MAPK mTOR Keap1-Nrf2 TGF-β Receptor Neurological Disease Metabolic Disease
    Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .
    Orcinol glucoside
  • HY-135140A
    Methyltetrazine-amine hydrochloride

    		Biochemical Assay Reagents Others
    Methyltetrazine-Amine hydrochloride is a tetrazine compound. Methyltetrazine-Amine hydrochloride can be used for the site-specific dual functionalization of the resulting bioconjugates. Methyltetrazine-Amine hydrochloride can be added during protein precipitation in experiments using trans-cyclooctene .
    Methyltetrazine-amine hydrochloride
  • HY-121087
    BCI-215
    3 Publications Verification

    		 Phosphatase Cancer
    BCI-215 is a potent and tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells .
    BCI-215
  • HY-14362
    GSK-25

    		ROCK Ribosomal S6 Kinase (RSK) Cardiovascular Disease
    GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 µM for CYP2C9, CYP2D6, CYP3A4, respectively) .
    GSK-25
  • HY-N1050
    Zederone

    		mTOR Ribosomal S6 Kinase (RSK) Bacterial Infection Neurological Disease Cancer
    Zederone is a sesquiterpene. Zederone inhibits ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway. Zederone inhibits CYP activities with IC50s of 2.9 μM (CYP2B6), 9.2 μM (CYP2C9), 11,2 μM (CYP2C19) and >30 μM (CYP1A2 and CYP2D6). Zederone is hepatotoxic with LD50 value at 24 hours in mice of approximately 223 mg/kg and cytotoxic against the KG1a cell line. Zederone shows antibacterial activity against a number of multi-drug resistant and Methicillin (HY-121544)-resistant Staphylococcus aureus strain. Zederone shows cognition improving capacity and assists in the modulation of gut bacterial dysbiosis .
    Zederone
  • HY-176428
    PROTAC MNK1 degrader-1

    P11-2

    		 PROTACs MNK Apoptosis Eukaryotic Initiation Factor (eIF) Cancer
    PROTAC MNK1 degrader-1 is a selective MNK1 PROTAC degrader with a DC50 of 11.92 nM, and a Dmax > 96% in MV4-11 cells. PROTAC MNK1 degrader-1 significantly reduces p-eIF4E (IC50: 22.07 nM), induces apoptosis, and arrests the cell cycle at the G1 phase. PROTAC MNK1 degrader-1 has potent antitumor activity. PROTAC MNK1 degrader-1 has robust antileukemic efficacy in MV4-11 xenograft mice model with acceptable drug safety . Pink: MNK1 ligand (HY-176429); Blue: CRBN ligase ligand (HY-A0003); Black: linker (HY-Y1139); CRBN + linker: HY-176430
    PROTAC MNK1 degrader-1
  • HY-112113
    SLV-2436

    SEL201-88; SEL-201

    		 MNK Cancer
    SLV-2436 is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50s of 10.8 nM and 5.4 nM, respectively.
    SLV-2436
  • HY-152944
    S6K1-IN-DG2

    		Ribosomal S6 Kinase (RSK) Cancer
    S6K1-IN-DG2 (Compound 66) is a p70S6K inhibitor (IC50: < 100 nM) .
    S6K1-IN-DG2
  • HY-148877
    AT-533

    		HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK Infection Inflammation/Immunology Cancer
    AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .
    AT-533
  • HY-N0597
    Panaxatriol
    3 Publications Verification

    		 Akt Insulin Receptor Apoptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Metabolic Disease Cancer
    Panaxatriol is an orally active dammarane-type tetracyclic triterpene sapogenin. Panaxatriol enhances the phosphorylation levels of Akt, insulin receptor and p70S6K in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer [1][2][3].
    Panaxatriol
  • HY-134903
    (32-Carbonyl)-RMC-5552

    		mTOR Cancer
    (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .
    (32-Carbonyl)-RMC-5552
  • HY-P10042
    S6K Substrate

    		Ribosomal S6 Kinase (RSK) Others
    S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .
    S6K Substrate
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR GLP Receptor Inflammation/Immunology
    GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-12059A
    AT7867 dihydrochloride
    5 Publications Verification

    		 Akt PKA Ribosomal S6 Kinase (RSK) Cancer
    AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
    AT7867 dihydrochloride
  • HY-124645
    QL-X-138

    		Flavivirus Dengue Virus Btk MNK Infection Cancer
    QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies .
    QL-X-138
  • HY-153476A
    GIP/GLP-1 dual receptor agonist-1 sodium

    		GLP Receptor GCGR Inflammation/Immunology
    GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1 sodium
  • HY-146805
    EB1

    		MNK Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation .
    EB1
  • HY-13260A
    CCT128930 hydrochloride
    5+ Cited Publications

    		 Akt Autophagy Apoptosis Cancer
    CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .
    CCT128930 hydrochloride
  • HY-13787
    XL-418

    		Akt Ribosomal S6 Kinase (RSK) GSK-3 Cancer
    XL-418 is an orally active dual Akt and p70S6K inhibitor with IC50s of 1 nM for Akt1 and 2 nM for p70S6K. XL-418 inhibits the phosphorylation of ribosomal protein S6 and GSK3β. XL-418 can be used for the study of prostate carcinoma and breast cancer .
    XL-418
  • HY-147187
    MNK8

    		STAT Apoptosis Bcl-2 Family Survivin Cancer
    MNK8 is a potent STAT3 (signal transducer and activator of transcription 3) inhibitor. MNK8 inhibits STAT3 activation and reduced its DNA binding ability. MNK8 shows good growth inhibition against hepatocellular carcinoma (HCC) cells. MNK8 induces apoptosis in HCC cells. MNK8 reduces prosurvival proteins expression and migration/invasion of HCC cells .
    MNK8
  • HY-124638
    MNK inhibitor 9

    		MNK Cancer
    MNK inhibitor 9 is a potent and selective inhibitor of MNK1/2 with IC50 values of 0.003 µM and 0.003 µM for MNK1 and MNK2 respectively. MNK inhibitor 9 has good cell permeability. MNK inhibitor 9 can be used in tumor related research .
    MNK inhibitor 9
  • HY-12493
    LY-2584702 free base

    		Ribosomal S6 Kinase (RSK) Cancer
    LY-2584702 free base is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
    LY-2584702 free base
  • HY-130723A
    AMPK activator 2 hydrochloride

    		AMPK Cancer
    AMPK activator 2 (compound 7a) hydrochloride, a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 hydrochloride inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .
    AMPK activator 2 hydrochloride
  • HY-N11709
    Theasaponin E1

    		Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal Infection Neurological Disease Metabolic Disease Cancer
    Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .
    Theasaponin E1
  • HY-114038
    SB-747651A

    		p38 MAPK Inflammation/Immunology
    SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research .
    SB-747651A
  • HY-126257
    AKT-IN-3

    		Akt Apoptosis Cancer
    AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .
    AKT-IN-3
  • HY-13595R
    Chrysophanol (Standard)

    Chrysophanic acid (Standard)

    		 Reference Standards EGFR Cancer
    Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.
    Chrysophanol (Standard)
  • HY-W171935
    MNK-IN-5

    		MNK Others
    MNK-IN-5 is a MNK inhibitor that suppresses MNK activity .
    MNK-IN-5
  • HY-170772
    Dual Cathepsin L/JAK-IN-1

    		p38 MAPK STAT Interleukin Related Cathepsin JAK Inflammation/Immunology
    Dual Cathepsin L/JAK-IN-1 (Compound A8) is a dual inhibitor of Cathepsin L (CTSL) and JAK, with IC50 values of 0.68 μM, 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for CTSL, JAK1/2/3, and TYK2, respectively. Dual Cathepsin L/JAK-IN-1 effectively blocks the activation of the MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. Dual Cathepsin L/JAK-IN-1 can be used in research on acute lung injury (ALI) .
    Dual Cathepsin L/JAK-IN-1
  • HY-124891
    1-Phenylpyrrole

    N-Phenylpyrrole

    		 Fluorescent Dye Others
    1-Phenylpyrrole (N-Phenylpyrrole) has dual fluorescent properties. 1-Phenylpyrrole displays a single band in nonpolar solvents and a second red-shifted fluorescent band in polar solvents .
    1-Phenylpyrrole
  • HY-124348
    DM-PIT-1

    3,5-Dimethyl PIT-1

    		 PI3K Cancer
    DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer .
    DM-PIT-1
  • HY-120035
    DD1

    		Proteasome Ribosomal S6 Kinase (RSK) Apoptosis Cancer
    DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation .
    DD1
  • HY-12493B
    LY-2584702 hydrochloride

    		Ribosomal S6 Kinase (RSK) Cancer
    LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
    LY-2584702 hydrochloride
  • HY-P10042A
    S6K Substrate acetate

    		Ribosomal S6 Kinase (RSK) Others
    S6K Substrate acetate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .
    S6K Substrate acetate
  • HY-173119
    SKLB-D18

    		ERK Autophagy Apoptosis p62 mTOR Reactive Oxygen Species (ROS) Ferroptosis Cancer
    SKLB-D18 is an orally active ERK1/2/ERK5 inhibitor, with an IC50 of 38.69 nM and a Kd of 126.9 nM against human ERK1, an IC50 of 40.12 nM and a Kd of 209.8 nM against ERK2, and an IC50 of 59.72 nM and a Kd of 468.2 nM against ERK5. SKLB-D18 inhibits cancer cell proliferation, induces G0/G1 cell cycle arrest and apoptosis. SKLB-D18 reduces the levels of p-ERK5, p-RSKp90, p-c-Myc and c-Myc, and upregulates the level of p-ERK1/2, thereby inhibiting the ERK1/2/5 pathway in cells. SKLB-D18 increases LC3B-II accumulation, and decreases the levels of p62, p-mTOR and p-p70S6K. SKLB-D18 elevates the levels of ROS, lipid peroxidation and free ferrous ions, reduces the levels of NCOA4 and GPX4, and induces ferritin autophagy-dependent ferroptosis in cancer cells. SKLB-D18 exhibits antitumor activity in a triple-negative breast cancer xenograft mouse model. SKLB-D18 can be used in research related to triple-negative breast cancer .
    SKLB-D18

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: